In the phase 1/2 (ALL‐RET) study of alectinib, the TE incidence was 2.9% (one case of TE occurred in 34 patients) [40], while no TEs were reported in the phase II clinical trial of ponatinib for advanced NSCLC with RET fusions [41]. Here, RET is linked to non-small cell lung carcinoma.